Stock listing
ELOX Stock Price, News, Filings & Events — Eloxx Pharmaceuticals, Inc.
Selected listing: ELOX · NASDAQ · USD · US
This page tracks Eloxx Pharmaceuticals, Inc.'s ELOX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ELOX:NASDAQ. ELOX:NASDAQ is the stock-level entry point for investors researching Eloxx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eloxx Pharmaceuticals, Inc. is a public company traded under the ticker ELOX in the American market, with a market capitalization of approximately $495.3 million. The company focuses on developing innovative therapies for genetic diseases caused by nonsense mutations. Eloxx aims to address significant unmet medical needs through its research and development efforts.
- Ticker
- ELOX:NASDAQ
- Asset type
- Stock
- Market cap
- $63.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Eloxx Pharmaceuticals, Inc. ELOX:NASDAQ stock context
This page tracks Eloxx Pharmaceuticals, Inc.'s ELOX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ELOX:NASDAQ. ELOX:NASDAQ is the stock-level entry point for investors researching Eloxx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eloxx Pharmaceuticals, Inc. is a public company traded under the ticker ELOX in the American market, with a market capitalization of approximately $495.3 million. The company focuses on developing innovative therapies for genetic diseases caused by nonsense mutations. Eloxx aims to address significant unmet medical needs through its research and development efforts.
Latest news from Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 11, 2026
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity
May 5, 2026
ELOX: Sixth Amendment adds bridge and Tranche 2 loans, PIK interest, and new agent SD MF 4 LLC
March 17, 2026
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
Research Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for ELOX:NASDAQ.
Eloxx Pharmaceuticals, Inc. company profile
View the public company page for Eloxx Pharmaceuticals, Inc. on 6ix.
Eloxx Pharmaceuticals, Inc. news
Read company news and market updates connected to Eloxx Pharmaceuticals, Inc..
Eloxx Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Eloxx Pharmaceuticals, Inc..